Industry Insights

  1. How A Problematic Database Project Inspired Me To Revamp eClinical Software
    5/16/2019

    Mike Novotny, founder and CEO of Medrio, shares an experience from early in his career of building databases that showed him by having the right data at the right time, doctors can make decisions allowing patients to live their best lives possible.

  2. Conducting The Advanced Therapy Supply Chain Orchestra
    5/14/2019

    Conducting the advanced therapy supply chain orchestra is more than waving a stick at people – it is an “end to end”, complicated, inter-related system that requires controlled, consistent management. Following are some things you need to think about to develop the capability to provide a harmonious supply chain management system.

  3. EudraVigilance Survival Guide
    5/14/2019

    What it is, why it is important, and what sponsors need to think about as it gets closer.

  4. Importance Of Chain Of Custody Documentation For Biologics
    5/10/2019

    Preventing patients from receiving “counterfeit, diverted, sub-potent, substandard, adulterated, misbranded, or expired drugs” is a critical element of the mission of the US Food and Drug Administration (FDA). Chain of custody for genetic and cell therapies differs and is more complex than for traditional pharmaceuticals, and the requirements for documentation vary as well.

  5. Practical Considerations For Patient-Focused Data Collection In Oncology Trials
    5/9/2019

    Read how new initiatives reinforce the importance of the patient’s voice, acknowledge the limitations of traditional approaches and build on the lessons that emerge from each new study.

  6. Ask The IRB Experts
    5/9/2019

    Clinical research is complicated.  At WCG, we frequently get questions about the ethical conduct of research from clinical team members at biopharma companies and study sites. We know that for many of the questions we get, the person asking is not the only one struggling with that issue. Read the questions your peers are asking – and if you don’t see yours, submit one of your own.

  7. Not Enrolling Enough? How To Rescue Your Recruitment
    5/8/2019

    A common issue regarding “faltering” studies – studies that are not satisfying their time, cost, and quality parameters – is poor recruitment. Recruitment issues can delay deadlines and jeopardize the drug’s ultimate approval, if left unresolved. If your study is struggling because of recruitment issues, here are some considerations that can be used to rescue your clinical trial.

  8. Is Your Clinical Trial In Need Of A Rescue?
    5/8/2019

    Don’t assume your clinical trial will survive endless change orders, extended deadlines, cost overruns, and missed objectives. Recognizing early warning signs that your trial is in trouble, and taking quick decisive action, can often get studies back on track. Improving operations can solve most failure risk factors, thus increasing the odds of success.

  9. Determining The "ROI" Of Clinical Trial Rescue Before It's Too Late
    5/8/2019

    The longer you addressing a faltering clinical trial, the greater the risk your trial progresses from faltering to failure. And the deeper a trial's problems, the more likely you'll have to ask for a substantial budget increase—another difficult conversation. Here are some tips to act quickly for the best ROI.

  10. Untapped Potential: Asia-Pacific’s Growing Role In Biotech Drug Research
    5/7/2019

    For all its demographic promise, the Asia-Pacific (APAC) region has been slow to emerge as a center for US and EU biotech clinical drug research. Patient access in this region is now a strong motivator. Read further observations about the future of the APAC region in biotech drug research.